SVA - Sinovac Biotech's Omicron-specific vaccine cleared for clinical trial in Hong Kong

Sinovac Biotech's (NASDAQ:SVA) Omicron-specific vaccine was approved for clinical trials in Hong Kong. Sinovac, a unit of Sinopharm Group (OTCPK:SHTDF) (OTCPK:SHTDY), said preclinical studies showed that the SINOVAC Omicron variant inactivated vaccine was safe and effective in animals following which it submitted clinical applications in several countries and regions at the end of February. The company said in an April 14 press release that the clinical approval in Hong Kong is the first clinical approval for the SINOVAC Omicron strain inactivated vaccine.

For further details see:

Sinovac Biotech's Omicron-specific vaccine cleared for clinical trial in Hong Kong